Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial

Published:2024-04 Issue:4 Volume:11 Page:e287-e298
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Bazinet Alexandre,Kantarjian Hagop,Bataller Alex,Pemmaraju Naveen,Borthakur Gautam,Chien Kelly,Alvarado Yesid,Bose Prithviraj,Jabbour Elias,Yilmaz Musa,DiNardo Courtney,Issa Ghayas,Montalban-Bravo Guillermo,Short Nicholas,Sasaki Koji,Bull-Linderman Debra,Daver Naval,Garcia-Manero Guillermo,Ravandi Farhad,Kadia Tapan

Funder

Genentech

University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Reference35 articles.

1. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial;Burnett;J Clin Oncol,2013

2. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients;Burnett;Blood,2015

3. Age and acute myeloid leukemia;Appelbaum;Blood,2006

4. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N Engl J Med,2020

5. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial;Wei;Blood,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?;Expert Review of Hematology;2024-07-21

2. Time to define and refine maintenance strategies in acute myeloid leukaemia;The Lancet Haematology;2024-04